- Previous Close
1.7400 - Open
1.7200 - Bid --
- Ask --
- Day's Range
1.7200 - 2.0400 - 52 Week Range
0.8400 - 2.9900 - Volume
2,626 - Avg. Volume
6,903 - Market Cap (intraday)
11.037M - Beta (5Y Monthly) 8.01
- PE Ratio (TTM)
-- - EPS (TTM)
-4.2500 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
eternatx.comRecent News: ERNA
View MorePerformance Overview: ERNA
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERNA
View MoreValuation Measures
Market Cap
9.47M
Enterprise Value
51.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
82.33
Price/Book (mrq)
--
Enterprise Value/Revenue
450.49
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.81%
Return on Equity (ttm)
-1,154.18%
Revenue (ttm)
115k
Net Income Avi to Common (ttm)
-22.91M
Diluted EPS (ttm)
-4.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
5.12M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.3M